Document:

<PAGE>
                                                                   EXHIBIT 10.14

                        COOPERATIVE DEVELOPMENT AGREEMENT

         This Cooperative Development Agreement (the "Agreement") is entered
into as of December 15, 2003 (the "Effective Date") by and between Nanosys Inc.
("Nanosys"), a Delaware corporation with a place of business at 2625 Hanover
Street, Palo Alto, California 94304 and Intel Corporation ("Intel"), a Delaware
corporation with a place of business at 2200 Mission College Boulevard, Santa
Clara, California 95052.

                                    RECITALS

Whereas:

         A.       Intel has expertise with respect to memory devices and the
development, design, and manufacture thereof, and Nanosys has expertise with
respect to the design and synthesis of nanomaterials and the development of
nanotechnology-enabled systems.

         B.       Intel and Nanosys desire to enter into an agreement to
cooperate to investigate the feasibility of using [*** Redacted] in memory
devices.

                                    AGREEMENT

NOW, THEREFORE, the parties agree as follows:

         1.       DEFINITIONS. In this Agreement, the following words and
expressions shall have the following meanings:

                  1.1 "Background IP" of a party means any and all intellectual
property rights that such party either (i) owned, controlled, or had rights with
respect to prior to the Effective Date; or (ii) develops, or acquires ownership,
control, or rights with respect to, during the term of this Agreement but which
is not Collaboration IP.

                  1.2 "CNDA" means the parties' October 11, 2002 Corporate
Non-Disclosure Agreement #5085138.

                  1.3 "Collaboration" means the research and development work
set forth in Exhibit A hereto.

                  1.4 "Collaboration Commencement Date" means the date of
commencement of the Collaboration under Section 2.1 below.

                  1.5 "Collaboration IP" shall mean (i) all Intellectual
Property rights in Collaboration Technology, which Intellectual Property rights
were created by the parties' Listed Representatives (solely or jointly) in the
course of working on the Collaboration and (ii) all Intellectual Property of
either party conceived or created by or for either party ("Party") prior to the
termination or

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.
<PAGE>

expiration of the Collaboration based on the other party's Confidential
Information disclosed to such Party in connection with the Collaboration.

                  1.6 "Collaboration Right" means any patent, patent right (or
similar right under foreign law), utility model, copyright or mask work right
issued or registered as a result of a Filing.

                  1.7 "Collaboration Technology" means (i) any and all
Technology that either party's Listed Representatives conceive (solely or
jointly) in the course of working on the Collaboration, and (ii) any and all
Technology conceived (solely or jointly) prior to the termination or expiration
of the Collaboration by or for either party ("Party") based on Confidential
Information of the other party disclosed to such Party in connection with the
Collaboration, but, in each case, excluding Technology resulting from
University/Government Activities.

                  1.8 "Confidential Information" is defined in the CNDA, as set
forth in Section 6 below.

                  1.9 "Conventional Processes" means standard semiconductor
manufacturing processes (where "standard" semiconductor manufacturing processes
may include Intel proprietary semiconductor manufacturing processes) and
reasonable incremental improvements (e.g. standard  processes)
thereof, including those resulting in one or more features of [*** Redacted] of
[*** Redacted], and the resultant devices fabricated using such standard
semiconductor manufacturing processes (but excluding such resultant devices
incorporating Deposited Nanomaterials).

                  1.10 "Deposited Nanomaterials" means shape or size controlled
[*** Redacted], such as [*** Redacted], and [*** Redacted], having at least one
cross sectional dimension of less than 500 nanometers and such that the size
related properties of the nanomaterials are advantageous to their function, that
are subsequently [*** Redacted] as such nanomaterials [*** Redacted]

                  1.11 "Exclusivity Date" means the earlier of (i) the
Collaboration Commencement Date or (ii)  March 31, 2004.

                  1.12 "Exclusivity Period" means the period from the Effective
Date until the earlier of (i) March 31, 2006, (ii) the Exclusivity Expiration
(as defined in Section 3.3 below), or (iii) any termination of this Agreement.

                  1.13 "Field of Interest" means memory devices based on
[*** Redacted] used primarily as [*** Redacted] (e.g. this would not include
[*** Redacted] devices, [*** Redacted], or [*** Redacted]).

                  1.14 "Filing" means any application for or registration of a
patent, patent right (or similar right under foreign law), utility model,
copyright or mask work right with respect to Collaboration Technology.

                  1.15 "Intel's Exclusive Field" means (i) compositions,
devices, articles and methods involving or involved in memory and logic devices,
but only if such compositions, devices,

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -2-

<PAGE>

articles or methods are outside of Nanosys' Exclusive Field, and in each case
excluding Conventional Processes, and (ii) all Conventional Processes other than
Conventional Processes used in conjunction with Deposited Nanomaterials. For the
avoidance of doubt, (i) Conventional Processes used in conjunction with
Deposited Nanomaterials are not in Intel's Exclusive Field nor in Nanosys'
Exclusive Field and (ii) devices incorporating Deposited Nanomaterials are in
Nanosys' Exclusive Field.

                  1.16 "Intellectual Property" shall mean patents (and similar
rights under foreign law, and applications therefor), trade secrets, copyrights
and mask works.

                  1.17 "Listed Representatives" of a party means, at any time,
that party's employees, agents, and contractors then working on the
Collaboration on behalf of that party, as such individuals are identified by
that party by written notice to the other party. A party's notice of Listed
Representatives shall be in effect until a subsequent such notice by that party
modifying the list. Each party shall at all times in good faith maintain an
accurate list of Listed Representatives. At commencement, Intel's Listed
Representatives shall include [*** Redacted], and Nanosys' Listed
Representatives shall include [*** Redacted].

                  1.18 "Nanosys' Exclusive Field" means compositions, devices,
articles and methods involving or involved in Deposited Nanomaterials, but
excluding Conventional Processes.

                  1.19 "Nanosys Facility" means and includes Nanosys' operations
at 2625 Hanover Street in Palo Alto, CA, any ancillary engineering facilities
owned or controlled by Nanosys, and any successor facilities owned or controlled
by Nanosys during the term of this Agreement..

                  1.20 "Nanosys IP" shall mean Nanosys' Intellectual Property
Rights including Background IP and Collaboration IP.

                  1.21 "Technology" means any and all developments, ideas,
designs, inventions, information, know-how, and technology.

                  1.22 "University/Government Activities" means any and all
research, development, and other activities performed either (i) with any
university (or other educational institution) funding or any government or
government agency (U.S. or otherwise) funding, (ii) in collaboration with any
university (or other educational institution) or with any government or
government agency (U.S. or otherwise), or (iii) with a primary purpose of
obtaining government funding.

         2.       COLLABORATION WORK.

                  2.1 Each party shall use its commercially reasonable efforts
to perform its Collaboration obligations as set forth in Exhibit A. It is
understood and agreed that the Collaboration is in the nature of research, that
successful completion of the research is not assured, and that, so long as a
party uses its commercially reasonable efforts as set forth in the preceding
sentence, that party will not be in default for any failure to achieve any
particular result or to complete any particular deliverable. The parties shall
commence the Collaboration December 15, 2003, provided that on one or more
written notices to Nanosys received by Nanosys at least fifteen

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -3-

<PAGE>
[*** Redacted] prior to the date when the Collaboration is then scheduled to
commence (provided that if this Agreement is signed by Intel after November 30,
2003, Intel shall be entitled to provide the initial such notice on the date of
such signature, but only if such signature date is on or before December 10,
2003), Intel shall be entitled to delay commencement of the Collaboration to any
date on or before March 31, 2004. Delays resulting in commencement of the
Collaboration after December 31, 2003 shall be subject to the payments in
Section 3.2 below. It is understood and agreed that commencement of the
Collaboration may not be delayed past March 31, 2004.

                  2.2 Nanosys agrees to allocate to the Collaboration at least
[*** Redacted] full-time equivalent individuals during the first quarter of the
Collaboration, at least [*** Redacted] full-time equivalent individuals during
the second quarter of the Collaboration, at least [*** Redacted] full-time
equivalent individuals during the third quarter of the Collaboration, and at
least "X" full-time equivalent individuals (FTEs) during the fourth quarter of
the Collaboration, where "X" is a number between [*** Redacted] and
[*** Redacted], inclusive, chosen by Intel by written notice to Nanosys at least
[*** Redacted] days prior to the beginning of such fourth quarter. If Intel
fails to provide such notice, "X" will be deemed to equal [*** Redacted].

                  2.3 It is the parties' mutual intent that most of the work and
deliverable creation under this Agreement to investigate [*** Redacted] memory
feasibility shall occur at the Nanosys Facility. Nanosys shall host Intel's
Listed Representatives on a mutually agreed upon basis, such agreement not to be
unreasonably withheld, on site at the Nanosys Facility to work on this project
and get deeply involved in complementary collaborative activities (e.g., device
integration and characterization, but not the synthesis of Deposited
Nanomaterials). Information on the design and modeling of Deposited
Nanomaterials, as well as [*** Redacted], [*** Redacted], and [*** Redacted]
related to Deposited Nanomaterials, shall be provided to Intel's Listed
Representatives, but in each case only as reasonably required for device
integration and characterization for the purpose of the Collaboration, including
but not limited to, making an informed decision about the complexity of
integrating Deposited Nanomaterials with Conventional Processes. Nanosys' Listed
Representatives may also be invited to work at Intel's facilities, for
circumstances including but not limited to, using a metrology tool that may not
be available at the Nanosys Facility. The parties shall adhere to the following
guidelines in connection with Listed Representatives working at the site of the
other party: (a) all employees of one party visiting the other party's facility
shall comply with the rules and regulations applicable at that facility as
communicated to such employees, and each party retains the right to reasonably
refuse admittance for violation of these rules; (b) the hosting party shall
maintain reasonable firewall procedures so that employees of a visiting party
are not exposed to the confidential information of a third party; (c) each party
shall maintain reasonable firewall procedures so that third parties at a party's
site are not exposed to the confidential information of the other party or
non-public information about the status of this Collaboration; and (d) in the
case of Nanosys only, cubicle space, secure Internet access, and badge access
shall be made available for use by Intel's Listed Representatives when such a
person or persons are working on site at the Nanosys Facility.

                  2.4 Except as set forth in Section 5, any and all materials
supplied by one party to the other party shall be used by the recipient only to
perform its Collaboration obligations.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -4-

<PAGE>

                  2.5 Except as set forth in Section 3 below, each party shall
bear its own costs and expenses in carrying out the Collaboration.

                  2.6 Except for University/Government Activities, each party
agrees to work exclusively with the other party in the Field of Interest during
the Exclusivity Period.

                  2.7 The following persons ("Collaboration Managers") shall be
appointed to direct the conduct of the parties with respect to the
Collaboration:

                       (a)  For Intel:          Eric Hannah
                                                Sector Director, Intel Research
                                                Intel Corporation
                                                2200 Mission College Blvd.
                                                Mail Stop RN6-661
                                                Santa Clara, CA 95052
                                                Phone:  408-765-4441
                                                Fax:    408-765-6271
                                                E-mail: eric.hannah@intel.com

                       (b)  For Nanosys:        Calvin Y.H. Chow
                                                Chief Executive Officer
                                                Nanosys Inc.
                                                2625 Hanover Street
                                                Palo Alto, CA 94304
                                                Phone: (650) 331-2102
                                                Fax: (650) 331-2101
                                                E-mail: cchow@nanosysinc.com

The Collaboration Managers shall have the authority to approve in writing
changes to Exhibit A, including, as applicable, specifications, scope of work,
and milestones. The Collaboration Managers shall have no other authority to
amend this Agreement. Each party may change its Collaboration Manager on written
notice to the other party, provided that the replacement Collaboration Manager
is at a similar level of authority at the party making the replacement, or as
otherwise agreed by the parties.

                  2.8 If either party desires to propose changes to the
Collaboration, it shall notify the other party in writing of such proposal and
the reasons for such proposal. The other party will give each such proposal its
prompt attention. If Intel and Nanosys agree to any such change, the change
shall be evidenced by a written confirmation signed by the Collaboration
Managers of both parties. Such a written confirmation shall amend the terms of
Exhibit A.

                  2.9 If the Collaboration is completed successfully (i.e.,
neither party has terminated this Agreement under Section 10, and the parties
agree that the subject technology is promising and warrants pursuing further),
then it is the parties' intent that, at Intel's request, the parties will
negotiate, in good faith, during the Exclusivity Period to enter into a
follow-on development agreement (the "Development Agreement") to further develop
and commercialize the technology

                                                                             -5-

<PAGE>

which is the subject of this Agreement If Intel requests such a negotiation,
then, for the duration of the Exclusivity Period, Nanosys agrees that Nanosys
will not enter into any discussions regarding the subject of the Collaboration
with any third party. The parties further intend that any such Development
Agreement would reflect that, if the development and commercialization of this
technology are successful, and Intel has a good-faith intent to use the
Collaboration Materials in anticipation of a high-volume manufacturing ramp,
then:

                           (a)      It is the parties' mutual intent that the
parties would negotiate in good faith a supply agreement that reasonably assures
the supply of Deposited Nanomaterials and any related Nanosys enabling
technology or rights to Intel (for use in the Field of Interest, the
"Collaboration Materials"). Upon Intel's request to commence such negotiations,
the parties would negotiate diligently and in good faith to reach agreement.
Further, if at the expiration of the Development Agreement the parties have not
reached agreement, notwithstanding their diligent and good faith efforts, then
Nanosys would not enter into any supply agreement, within six (6) months after
the expiration of the Development Agreement, to supply Collaboration Materials
to any third party, in the Field of Interest, on terms which are more favorable
to that third party than the terms last offered by Nanosys to Intel during this
negotiation. In the first instance, the parties would use reasonable efforts to
qualify Nanosys as a supplier to Intel of the Collaboration Materials. Nanosys
acknowledges that, in order to be selected as an Intel qualified supplier,
Nanosys must demonstrate supply capability (in areas including, but not limited
to, cost, quality, and availability). Nanosys further acknowledges that the
supply agreement would include a "most favored customer" provision which
guarantees that, at any time, Nanosys' price to Intel for Collaboration
Materials is no higher than the price charged by Nanosys to any third party for
Collaboration Materials, in the Field of Interest, on similar terms and
conditions. Further, if the parties enter into a supply agreement, the supply
agreement will include provisions to help ensure a reliable supply of
Collaboration Materials to Intel, which may include (i) safety stock and (ii) if
Nanosys is unable to reasonably provide Intel with the Collaboration Materials,
then upon notice from Intel, Nanosys' would take prompt action to arrange for
such supply, which may include designating a subcontractor, subject to Intel's
consent of such subcontractor (which shall not be unreasonably withheld), to
manufacture such quantity of Collaboration Materials that cannot be obtained
from Nanosys, providing such subcontractor agrees to pay Nanosys a reasonable
royalty and agrees to reasonable confidentiality, intellectual property
protection, and commercial provisions. Nanosys agrees to fully reasonably
cooperate with Intel and the chosen subcontractor in the transfer of technology
and sufficient collaborative engineering resources necessary to allow the
subcontractor to produce Collaboration Materials for Intel's intended use as
soon as practicable after Intel's request. Nanosys reserves the right to seek
any and all legal recourse against the subcontractor if confidentiality or other
provisions of the agreement between Nanosys and the subcontractor are violated.

                           (b)      It is the parties' mutual intent that, if
the parties have not entered into a supply agreement as set forth in Section
2.9(a), notwithstanding their diligent and good faith efforts, then upon Intel's
request within [*** Redacted] after the expiration of the Development
Agreement, Nanosys would designate a contract manufacturer, subject to Intel's
consent of such contract manufacturer (which would not be unreasonably
withheld), to manufacture Collaboration Materials, licensing such contract
manufacturer to applicable Nanosys intellectual property on reasonable and
non-discriminatory terms, provided that such contract manufacturer agrees to pay
Nanosys a reasonable royalty and agrees to reasonable confidentiality,
intellectual property

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -6-

<PAGE>
protection, and commercial provisions. Nanosys shall fully and reasonably
cooperate with Intel and the chosen contract manufacturer in the transfer of
technology and sufficient collaborative engineering resources necessary to allow
the contract manufacturer to produce Collaboration Materials for Intel's
intended use as soon as practicable after Intel's request. Nanosys reserves the
right to seek all legal recourse against the contract manufacturer if
confidentiality or other provisions of the license between Nanosys and the
contract manufacturer are violated. If Nanosys fails to enter into a license
with a contract manufacturer as contemplated in this Section 2.9(b) within
[*** Redacted] after Intel's request to Nanosys, then Nanosys would be deemed
not to be entering the business of high-volume supply of Collaboration
Materials.

                           (c)      The parties further intend that if Nanosys
chooses not to enter into the business of supply of Collaboration Materials, and
Nanosys does not license the necessary enabling technology to a third party
manufacturer as provided in Section 2.9(b) above, then Nanosys would provide to
Intel a royalty-bearing, capped fee, worldwide, perpetual, non-exclusive license
under Nanosys IP, to have made Collaboration Materials and to make, have made,
use, sell, offer to sell and import, products using or incorporating
Collaboration Materials.

         3.       PAYMENTS TO NANOSYS.

                  3.1 Intel shall pay to Nanosys the following payments at the
following times:

<TABLE>
<CAPTION>
           TIME OF PAYMENT                                  AMOUNT OF PAYMENT
----------------------------------------                ------------------------
<S>                                                     <C>
Collaboration Commencement Date                             $   [*** Redacted].

Three (3) months after the Collaboration                    $   [*** Redacted].
Commencement Date

Six (6) months after the Collaboration                      $   [*** Redacted].
Commencement Date

Nine (9) months after the Collaboration                     $  [*** Redacted]*.
Commencement Date
</TABLE>

* $[*** Redacted] per FTE, according to the number of FTEs chosen by Intel,
pursuant to Section 2.2 above, for the fourth quarter of the Collaboration.

For the avoidance of doubt, the latter two payments (of $[*** Redacted] and
([*** Redacted])) will not be due if Intel terminates this Agreement under
Section 10.2 below.

                  3.2 For each month (or portion thereof) that Intel delays the
Collaboration Commencement Date, pursuant to Section 2.1 above, to a date after
December 31,2003, Intel shall pay to Nanosys [*** Redacted] dollars
($[*** Redacted]) (prorated on a day for day basis for partial months). Such
payment shall be due and payable within thirty (30) days after Intel's notice of
delay. (By way of example only, if upon execution of this Agreement Intel
notified Nanosys of a Collaboration Commencement Date delay to January 15,
2004, Intel would pay Nanosys $[*** Redacted] within thirty (30) days after such
notice date. If on December 15,2003 Intel then notified Nanosys of a further
delay

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -7-

<PAGE>

in the Collaboration Commencement Date, until March 10, 2004, Intel would
pay to Nanosys an additional $[*** Redacted] by January 14, 2004 (i.e., in
this example, a total of $[*** Redacted]).)

                  3.3 As of the Effective Date, the "Exclusivity Expiration"
shall be fifteen (15) months after the Exclusivity Date.

                           (i)      Intel shall be entitled to extend the
Exclusivity Expiration by three (3) months, to twenty-one (21) months after the
Exclusivity Date, by written notice to Nanosys no later than seventeen (17)
months after the Exclusivity Date, and payment to Nanosys of [*** Redacted]
dollars ($[*** Redacted]). This payment shall be due and payable no later than
eighteen (18) months after the Exclusivity Date.

                           (ii)     If Intel has extended the Exclusivity
Expiration pursuant to paragraph (i) hereinabove, then Intel shall be entitled
to further extend the Exclusivity Expiration by an additional [*** Redacted], to
[*** Redacted] after the Exclusivity Date, by written notice to Nanosys no later
than [*** Redacted] after the Exclusivity Date, and payment to Nanosys of [***
Redacted] dollars ($[*** Redacted]). This payment will be due and payable no
later than [*** Redacted] after the Exclusivity Date.

                           (iii)    If Intel has extended the Exclusivity
Expiration pursuant to paragraph (ii) hereinabove, then Intel shall be entitled
to further extend the Exclusivity Expiration by an additional [*** Redacted], to
[*** Redacted] after the Exclusivity Date, by written notice to Nanosys no later
than [*** Redacted] after the Exclusivity Date, and payment to Nanosys of [***
Redacted] dollars ($[*** Redacted]). This payment will be due and payable no
later than [*** Redacted] after the Exclusivity Date.

[*** Redacted] paid by Intel pursuant to this Section 3.3 may, at Intel's
option, be credited to [*** Redacted] of Intel to Nanosys under [*** Redacted]
by the parties, in the Field of Interest, entered into prior to termination of
the Exclusivity Period.

         4.       OWNERSHIP.

                  4.1 Each party shall retain its ownership of its Background
IP. No rights are granted pursuant to this Agreement with respect to any
Background IP.

                  4.2 Subject to the licenses set forth in Section 5 below,
Nanosys shall own all Collaboration IP. Subject to the licenses set forth in
Section 5 below, Intel irrevocably hereby agrees to, and hereby does, transfer,
convey and assign to Nanosys all of Intel's right, title, and interest in the
Collaboration IP, including without limitation all Intellectual Property rights
with respect thereto. Intel agrees to execute such documents, render such
assistance, and take such other action as Nanosys may reasonably request to
apply for, register, perfect, confirm, and protect Nanosys' rights in the
Collaboration IP. Subject to Sections 5, 6, and 7 below, ownership of
Collaboration Technology shall vest in Nanosys the exclusive right to determine
whether and how the Collaboration IP is to be protected and exercised throughout
the world.

         5.       LICENSES.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -8-

<PAGE>

                  5.1 Subject to the terms and conditions of this Agreement,
Nanosys agrees to grant, and hereby grants, to Intel a worldwide, nonexclusive
(except as set forth in Section 5.1(i) hereinbelow), nontransferable (except as
set forth in Section 11.7 below), royalty free license, only under Collaboration
IP, to design, develop, make, have made, use, import, offer to sell, and sell or
distribute any product or item and to practice any method or process, provided
that:

                           (i)      this license shall be exclusive (including
as to Nanosys) for use of the Collaboration IP in Intel's Exclusive Field, and

                           (ii)     no license is granted by Nanosys for use of
any Collaboration IP in Nanosys' Exclusive Field.

                  5.2 Intel shall have the right to grant sublicenses (and
authorize the granting of further sublicenses) under the license granted to it
in Section 5.1 above.

                  5.3 No party shall be obligated to provide any Technology or
deliverable in connection with the licenses granted in this Section 5; all
deliverables under this Agreement are specified exclusively in Exhibit A.

                  5.4 Notwithstanding this Section 5 or Section 2.4, nothing in
this Agreement shall be construed as preventing Intel or Nanosys employees from
using [*** Redacted] of the Confidential Information of the other party,
provided that such use of [*** Redacted] shall not grant to Intel or Nanosys any
implied license to any of the other party's [*** Redacted]. [*** Redacted] means
information in [*** Redacted] which is [*** Redacted]. An [*** Redacted] if the
[*** Redacted] the information for the purpose of [*** Redacted].

                  5.5 For purposes of this Section 5.5, the following
definitions apply:

         "Applicable Intel Patents" means those claims of Intel patents which
claim inventions conceived by Intel during the 24 months following the
termination or expiration of the Collaboration, which inventions were based on
Nanosys' Confidential Information.

         "Applicable Nanosys Patents" means those claims of Nanosys patents
which claim inventions conceived by Nanosys during the 24 months following
the termination or expiration of the Collaboration, which inventions were based
on Intel's Confidential Information.

         "Applicable Intel Sublicensable Patents" means those claims of Intel
patents which claim inventions conceived by Intel during the 12 months
following the termination or expiration of the Collaboration, which inventions
were based on Nanosys' Confidential Information.

         "Applicable Nanosys Sublicensable Patents" those claims of Nanosys
patents which claim inventions conceived by Nanosys during the 12 months
following the termination or expiration of the Collaboration, which inventions
were based on Intel's Confidential Information.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -9-

<PAGE>

                           (a)      Subject to the terms and conditions of this
Agreement, Nanosys agrees to grant, and hereby grants, to Intel a worldwide,
nonexclusive, nontransferable (except as set forth in Section 11.7 below),
[*** Redacted] license, only under the Applicable Nanosys Patents, to design,
develop, make, have made, use, import, offer to sell, and sell or distribute any
product or item and to practice any method or process, provided that this
license shall be limited to use within Intel's Exclusive Field and the Field of
Interest. Intel shall have the right to grant sublicenses (and authorize the
granting of further sublicenses) under the license granted to it in this Section
5.5(a), as provided in Section 5.5(b) below.

                           (b)      Under the licenses granted under Section
5.5(a) above, but only under Applicable Nanosys Sublicensable Patents, and only
outside of the Field of Interest, Intel shall have the right to grant
sublicenses (and authorize the granting of further sublicenses).

                           (c)      Subject to the terms and conditions of this
Agreement, Intel agrees to grant, and hereby grants, to Nanosys a worldwide,
nonexclusive, nontransferable (except as set forth in Section 11.7 below),
[*** Redacted] license, only under the Applicable Intel Patents, to design,
develop, make, have made, use, import, offer to sell, and sell or distribute any
product or item and to practice any method or process, provided that this
license shall be limited to use within Nanosys' Exclusive Field and the Field of
Interest. Nanosys shall have the right to grant sublicenses (and authorize the
granting of further sublicenses) under the license granted to it in this Section
5.5(c), as provided in Section 5.5(d) below.

                           (d)      Under the licenses granted under Section
5.5(c) above, but only under Applicable Intel Sublicensable Patents, and only
outside of the Field of Interest, Nanosys shall have the right to grant
sublicenses (and authorize the granting of further sublicenses).

         6.       CONFIDENTIAL INFORMATION.

                  6.1 The CNDA shall apply to this Agreement, provided that, for
purposes of this Agreement:

                           (i)      "Confidential Information" shall also
include information disclosed as a result of access to the other party's
premises or property, which information relates to any information in tangible
form subject to clause (i) of Section 1 of the CNDA, whether such disclosure or
access occurs prior to, concurrent with, or following the disclosure of such
information in tangible form.

                           (ii)     In Section 2 of the CNDA, "a need to know"
means a need to know for the purposes of this Agreement.

                           (iii)    The third sentence of Section 6 of the CNDA
shall not apply to this Agreement; rather, the Termination and Survival sections
of this Agreement shall govern the disposition of Confidential Information.

                           (iv)     If the CNDA is terminated, the terms and
conditions of the CNDA shall continue to apply to disclosures in connection with
this Agreement.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                            -10-

<PAGE>

                  (v) In addition, each party shall be entitled to disclose the
other party's Confidential Information to the extent such disclosure is required
by the order or requirement of a court, administrative agency, or other
governmental body; provided, that the party required to make the disclosure
shall provide at least fifteen (15) days (or such lesser period as may apply if
the party required to make the disclosure received fewer than fifteen (15) days
notice of the disclosure obligation), advance written notice thereof to enable
the other party to seek a protective order or otherwise prevent such disclosure.

         7.       INTELLECTUAL PROPERTY PROTECTION.

                  7.1 Nanosys IP. Nanosys shall have the sole right at its
expense to prepare, file and prosecute Filings related to any Collaboration
Technology, subject to Section 7.2 below.

                  7.2 Protection of Collaboration Technology. The parties shall
confer on (i) protection of Collaboration Technology (other than Collaboration
Technology developed solely by Nanosys) through Filings and/or through
maintenance of the Collaboration IP as a trade secret, and (ii) preparation,
filing, prosecution and maintenance of Filings and Collaboration Rights related
to Collaboration Technology (other than Collaboration Technology developed
solely by Nanosys). Nanosys shall be responsible for all Filing(s) in all
jurisdictions for Collaboration IP. Provided however, if only Intel wants to
protect a Collaboration development through a Filing on that development, then
Intel shall be entitled to do so, at its sole expense, and in such a case shall
be deemed sole owner of the affected Collaboration Right and Filing. In such
event, Intel shall be deemed to have granted to Nanosys a nonexclusive (except
as set forth hereinbelow), irrevocable, perpetual, fully paid, royalty free
license, with right to sublicense (and authorize the granting of further
sublicenses), only under such Collaboration Right, without restriction,
including to practice any process or method, and to design, develop, make, use,
have made, offer to sell, and sell or distribute any product or item, provided
that (A ) this license shall be exclusive (including as to Intel) for use of the
Collaboration Right in Nanosys' Exclusive Field and (B) no license is granted by
Intel for use of the Collaboration Right in Intel's Exclusive Field.

                  7.3 Infringement Prosecution.

                           (i)      Nanosys shall have the sole right to
prosecute claims of infringement or misappropriation of Collaboration IP, where
such infringement or misappropriation is primarily in Nanosys' Exclusive Field.
In each such case, Intel shall, at Nanosys' expense, take all actions reasonably
requested by Nanosys in such prosecution, subject to indemnification by Nanosys
of Intel for any liability to third parties resulting from such participation.

                           (ii)     Intel shall have the sole right to prosecute
claims of infringement or misappropriation of Collaboration IP where such
infringement or misappropriation is primarily in Intel's Exclusive Field. In
each such case, Nanosys shall, at Intel's expense, take all actions reasonably
requested by Intel in such prosecution (which may include participation as a
named plaintiff, subject to indemnification by Intel of Nanosys for any
liability to third parties resulting from such participation as a plaintiff).

                                                                            -11-
<PAGE>

                  7.4 Further Assurances. At any time or from time to time on
and after the date of this Agreement, each party shall at the request of the
other party (i) execute, and deliver or cause to be delivered, all such
consents, documents or further instruments of license, assignment, and transfer,
and (ii) take or cause to be taken all such other actions, in each case at the
other party's expense and as the other party may reasonably deem necessary or
desirable in order for the other party to obtain the full benefits of Section
4.2 and this Section 7 and the activities contemplated thereby.

         8.       WARRANTY DISCLAIMER.

         NEITHER NANOSYS NOR INTEL MAKES ANY WARRANTY OF ANY KIND, WHETHER
EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WITHOUT LIMITATION ANY
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. WITHOUT
LIMITING THE FOREGOING, ALL DELIVERABLES AND OTHER ITEMS ARE PROVIDED BY EACH
PARTY "AS IS," AND ALL LICENSES GRANTED BY EACH PARTY ARE GRANTED "AS IS."

         9.       LIMITATION OF LIABILITY.

         NEITHER PARTY SHALL HAVE ANY LIABILITY FOR COSTS OF SUBSTITUTE PRODUCTS
OR SERVICES, OR FOR ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT, SPECIAL OR INDIRECT
DAMAGES OR LIABILITIES, INCLUDING WITHOUT LIMITATION SUCH DAMAGES OR LIABILITIES
FOR LOSS OF REVENUE, LOSS OF BUSINESS, FRUSTRATION OF ECONOMIC OR BUSINESS
EXPECTATIONS, LOSS OF PROFITS, OR COST OF CAPITAL, REGARDLESS OF THE FORM OF THE
ACTION, WHETHER IN CONTRACT OR OTHERWISE, EVEN IF ANY REPRESENTATIVE OF A PARTY
HERETO HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL
EITHER PARTY'S LIABILITY UNDER THIS AGREEMENT EXCEED THE AMOUNTS PAID OR PAYABLE
BY INTEL TO NANOSYS UNDER THIS AGREEMENT, provided that, as to Intel, this shall
be in addition to Intel's obligation to pay such amounts. These limitations,
however, shall not apply to either party's liability, if any, (i) for
contribution or indemnity with respect to liability to third parties for
personal injury, death, or damage to tangible property, (ii) exceeding the scope
of the licenses in Section 5 (Licenses), (iii) breach of Section 6 (Confidential
Information), or (iv) infringement of the other party's intellectual property
rights.

         10.      TERM AND TERMINATION.

                  10.1 Term. This Agreement shall commence as of the Effective
Date and shall continue until the expiration of the Exclusivity Period, unless
earlier terminated as set forth herein.

                  10.2 Q2 Checkpoint. Intel shall be entitled to terminate this
Agreement, for its convenience, on notice to Nanosys at any time within ten (10)
days after completion of the "Q2 Formal Review Meeting" milestone in Exhibit A.

                  10.3 Termination Due to Bankruptcy, etc. In the event a party:
(i) becomes insolvent; (ii) voluntarily files or has filed against it a petition
under applicable bankruptcy or insolvency laws which such party fails to have
released within thirty (30) days after filing;

                                                                            -12-

<PAGE>

(iii) proposes any dissolution, composition or financial reorganization with
credit ors or if a receiver, trustee, custodian or similar agent is appointed or
takes possession with respect to all or substantially all property or business
of such party; or (iv) such party makes a general assignment for the benefit of
creditors; then the other party may terminate this Agreement by notice to the
non-terminating party.

                  10.4 Termination Due to Breach. Either party shall have the
right to terminate this Agreement if the other party is in material breach of
any material term or condition of this Agreement and fails to remedy such breach
within thirty (30) days after receipt of written notice of such breach given by
the non-breaching party. To terminate this Agreement, the nonbreaching party
must provide further written notice of such termination to the breaching party
prior to a cure of the breach.

                  10.5 Survival. Neither the termination nor expiration of this
Agreement shall relieve either party from its obligations to pay the other any
sums accrued hereunder. Upon the termination or expiration of this Agreement,
(i) Intel shall promptly return to Nanosys all Nanosys Confidential Information
and (ii) Nanosys shall promptly return to Intel all Intel Confidential
Information. The parties agree that their respective rights, obligations and
duties under Sections 1, 2.9, 4 (Ownership), 5 (Licenses), 6 (Confidential
Information), 7 (Intellectual Property Protection), 8 (Warranty Disclaimer), 9
(Limitation of Liability), 10.5 (Survival), and 11 (Miscellaneous) shall survive
any termination or expiration of this Agreement.

         11.      MISCELLANEOUS.

                  11.1 Announcement. On or after the Effective Date, Nanosys
shall be entitled to issue a press release pertaining to this Agreement, upon
written consent from Intel to the content of the press release.

                  11.2 Notices. All notices, requests, demands and other
communications given or made in accordance with the provisions of this Agreement
shall be in writing and shall be deemed to have been given (i) three days after
mailing when mailed (by registered or certified mail, postage paid, only), (ii)
on the date sent when made by facsimile transmission with confirmation of
receipt (with hard copy to follow by registered or certified mail, postage paid,
only), and (iii) on the date received when delivered in person or by courier,
provided that notices and communications with respect to administrative and
project matters (e.g., changes in meeting times and dates, program
specifications, and specific program development activities) (but not legal
matters or matters pertaining to or establishing rights under this Agreement),
may be provided by e-mail and will be deemed given when sent. All notices shall
be provided to the address set forth below or such other place as such party may
from time to time designate in writing. Each party may alter its address set
forth below by notice in writing to the other party, and such notice shall be
considered to have been given three (3) days after the sending thereof:

               If to Nanosys:         Nanosys Inc.
                                      2625 Hanover Street
                                      Palo Alto, California 94304
                                      Fax:(650)331-2101

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                            -13-

<PAGE>

                                      Attn: Calvin Y.H. Chow
                                      E-mail: cchow@nanosysinc.com

               with a copy, for matters pertaining to intellectual property, to:

                                      Nanosys Inc.
                                      2625 Hanover Street
                                      Palo Alto, California 94304
                                      Fax: (650) 331-2101
                                      Attn: Matt Murphy
                                      E-mail: mmurphy@nanosysinc.com

               If to Intel:           Intel Corporation
                                      2200 Mission College Blvd.
                                      Santa Clara, CA 95052
                                      ATTN: General Counsel

                  11.3 Amendment; Waiver. This Agreement may be amended,
modified or supplemented only by a writing that is signed by duly authorized
representatives of both parties and that specifically identifies the provision
or provisions of this Agreement being amended, modified or supplemented. No term
or provision hereof will be considered waived by either party, and no breach
excused by either party, unless such waiver or consent is in writing signed on
behalf of the party against whom the waiver is asserted. Without limiting the
foregoing, no consent by either party to, or waiver of, a breach by either
party, whether express or implied, will constitute a consent to, waiver of, or
excuse of any other, different, or subsequent breach by either party.

                  11.4 Severability. If any provision hereof should be held
invalid, illegal or unenforceable in any jurisdiction, the parties shall
negotiate in good faith a valid, legal and enforceable substitute provision that
most nearly reflects the original intent of the parties and all other provisions
hereof shall remain in full force and effect in such jurisdiction and shall be
liberally construed in order to carry out the intentions of the parties hereto
as nearly as may be possible. Such invalidity, illegality or unenforceability
shall not affect the validity, legality or enforceability of such provision in
any other jurisdiction.

                  11.5 Governing Law. This Agreement shall be governed by and
construed under the laws of the United States and the State of California, not
including its conflict of law provisions.

                  11.6 Force Majeure. Except for the payment of sums accrued,
neither party will be liable for any failure or delay in performance under this
Agreement due to fire, explosion, earthquake, storm, flood or other weather,
unavailability of necessary utilities or raw materials, war, insurrection, riot,
act of God or the public enemy, law, act, order, proclamation, decree,
regulation, ordinance, or instructions of government or other public
authorities, or any other event beyond the reasonable control of the party whose
performance is to be excused. If, however, a party's performance is prevented
for sixty (60) days, then the other party shall be entitled to terminate this
Agreement on written notice to the party suffering the force majeure at any time
prior to resumption of performance by the party suffering the force majeure.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                            -14-

<PAGE>

                  11.7 Assignment. Neither party may transfer or assign this
Agreement, whether by operation of law or otherwise, without the prior written
consent of the other party and any attempt to do so without such consent will be
void. This Agreement will bind and inure to the benefit of the parties and their
respective permitted successors and permitted assigns. Notwithstanding anything
in this Agreement, however, either party may assign this Agreement without the
other party's prior written consent to a successor to all or substantially all
of its assets pertaining to the Collaboration (e.g., the surviving entity in a
merger or consolidation in which it participates or to a purchaser of all or
substantially all of its assets pertaining to the Collaboration), so long as
such surviving entity or purchaser shall assume (expressly in writing or by
operation of law) the performance of all of the terms of this Agreement.

                  11.8 No Third Party Beneficiaries. No person or entity other
than Intel and Nanosys will have any rights or obligations pursuant to this
Agreement.

                  11.9 Relationship of the Parties. The parties to this
Agreement are independent contractors. There is no relationship of agency,
partnership, joint venture, employment, or franchise between the parties and
this Agreement is negotiated at arm' s length with both sides represented by
counsel of their choice. Neither party has the authority to bind the other or to
incur any obligation on its behalf. Any such act will create a separate
liability in the party so acting to any and all third parties affected thereby.

                  11.10 Counterparts. This Agreement may be executed in two
counterparts, each of which shall be deemed an original, but both of which
together shall constitute one and the same instrument. If this Agreement is
executed in counterparts, no signatory hereto shall be bound until both the
parties named below have duly executed or caused to be duly executed a
counterpart of this Agreement.

                  11.11 Confidentiality of Agreement. Subject to Section 6.1(v)
and Section 11.1, each party agrees that the existence of and the terms and
conditions of this Agreement shall be treated as confidential, provided,
however, that each party may disclose the terms and conditions of this
Agreement: (i) as required by any court or other governmental body; (ii) as
otherwise required by law; (iii) to legal counsel of the parties; (iv) in
connection with the requirements of a public offering or securities filing; (v)
in confidence, to accountants, banks, and financing sources and their advisors;
(vi) in confidence, in connection with the enforcement of this Agreement or
rights under this Agreement; or (vii) in confidence, in connection with a merger
or acquisition or proposed merger or acquisition, or the like.

                  11.12 Authority. Each party represents and warrants to the
other party at the Effective Date (i) that it has the legal right, power, and
authority to enter into this Agreement and to fully perform its obligations
under this Agreement, and (ii) that the performance of such obligations will not
conflict with any agreements, contracts or other arrangements to which it is a
party or by which it is bound.

                  11.13 Entire Agreement. This Agreement, including all Exhibits
to this Agreement, together with the CNDA (as set forth in Section 6 above),
constitutes the entire agreement between the parties relating to this subject
matter and supersedes all prior or simultaneous representations,

                                                                            -15-

<PAGE>

discussions, negotiations, letters of intent, and agreements, whether written or
oral, with respect to the subject matter hereof.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement on
the dates set forth below effective as of the Effective Date.

NANOSYS INC.                              INTEL CORPORATION

By: /s/ CALVIN CHOW                       By: /s/ PATRICK P GELSINGER
    -----------------------------             -----------------------------
Print Name: CALVIN CHOW                   Print Name: PATRICK P GELSINGER
Title: CEO                                Title: Sr VP / CTO

                                                        LEGAL  OK
                                                        ----------
                                                        p  12/8/03

                                                                            -16-

<PAGE>

                                    EXHIBIT A

                  Collaboration Statement of Work (SOW) Summary

         Construction of [*** Redacted] devices (similar to the concept figure
below) to evaluate key technical areas required for a [*** Redacted] memory unit
and to project the performance limits of the technology.

                                 [*** Redacted]

         Device will have an [*** Redacted] and will be utilized to evaluate:

         -        [*** Redacted] and [*** Redacted].

         -        [*** Redacted] characteristics (e.g. [*** Redacted], etc.)

         -        [*** Redacted] - including [*** Redacted] characteristics.

         -        Effects of [*** Redacted], and [*** Redacted] modifications.

         -        Variations of [*** Redacted].

         -        [*** Redacted] (e.g. [*** Redacted])

         -        Variations of processing means.

         and to construct a model for [*** Redacted] of a [*** Redacted] or [***
Redacted] device.

In Q1 and Q2, the project would focus on modeling and generating/testing
[*** Redacted] in order to reconcile the validity of the model. Q3 and Q4 would
focus on a [*** Redacted] to better select [*** Redacted]. The [*** Redacted]
work would be done on [*** Redacted] devices in a [*** Redacted]. A more
detailed plan of activities will be generated by the Collaboration team upon
Commencement of the Collaboration.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

<PAGE>
The parties will hold a Q2 Formal Review Meeting no later than two weeks
after the end of Q2.

                                                                             -2-<PAGE>

                                                                   EXHIBIT 10.15

                        COOPERATIVE DEVELOPMENT AGREEMENT

     This Cooperative Development Agreement (the "Agreement") is entered into as
of January 22, 2004 (the "Effective Date") by and between Nanosys Inc.
("Nanosys"), a California corporation with a place of business at 2625 Hanover
Street, Palo Alto, California 94304 and E.I. du Pont de Nemours and Company
("DuPont"), a Delaware corporation with a place of business at 1007 Market
Street, Wilmington, DE 19898.

                                    RECITALS

     Whereas:

     A. DuPont has expertise with respect to [*** Redacted] using DuPont's
[*** Redacted] and the development, design, and manufacture thereof, and Nanosys
has expertise with respect to the design and synthesis of nanomaterials and the
development of nanotechnology-enabled systems.

     B. DuPont and Nanosys desire to enter into an agreement to cooperate to
investigate the commercial feasibility of combining Nanosys' [*** Redacted]
nanomaterials technology with DuPont's [*** Redacted] technology for
high-performance [*** Redacted] applications

                                    AGREEMENT

     NOW, THEREFORE, the parties agree as follows:

     1. DEFINITIONS. In this Agreement, the following words and expressions
shall have the following meanings:

          1.1 "Collaboration" means the research and development work set forth
in Exhibit A hereto.

          1.2 "Statement of Work ("SOW")" means Exhibit A hereto.

          1.3 "Collaboration Commencement Date" means the date of commencement
of the Collaboration under Section 2.1 below.

          1.4 "Technology" means any and all developments, ideas, designs,
inventions, information, know-how, and technology.

          1.5 "Collaboration Technology" of a party ("Party") means (i) any and
all Technology that such Party's employees or contractors conceive or develop
(solely or jointly) in the course of working specifically on the Collaboration,
and (ii) any and all Technology conceived or developed (solely or jointly) by or
for such Party based on Confidential Information of the other party disclosed to
such Party in connection with, or generated under, the Collaboration.

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.
<PAGE>
         1.6 "Nanosys Collaboration IP" shall mean (i) Nanosys' intellectual
property rights in Collaboration Technology of Nanosys, which intellectual
property rights were created by Nanosys' employees or contractors (solely or
jointly) in the course of specifically working on the Collaboration and (ii) all
intellectual property of Nanosys created by or for Nanosys based on DuPont
Confidential Information disclosed to Nanosys in connection with, or DuPont
Confidential Information generated under, the Collaboration.

         1.7 "DuPont Collaboration IP" shall mean (i) DuPont's intellectual
property rights in Collaboration Technology of DuPont, which intellectual
property rights were created by DuPont's employees or contractors (solely or
jointly) in the course of specifically working on the Collaboration and (ii) all
intellectual property of DuPont created by or for DuPont based on Nanosys
Confidential Information disclosed to DuPont in connection with, or Nanosys
Confidential Information generated under, the Collaboration.

         1.8 "Background IP" of a party means any and all intellectual property
rights that such party either (i) owned, controlled, or had rights with respect
to prior to the Effective Date; or (ii) develops, or acquires ownership,
control, or rights with respect to, during the term of this Agreement but which
is not that party's Collaboration IP.

         1.9 "Nanosys [*** Redacted] Nanomaterials Technology" means (i)
[*** Redacted] semiconductors formed as [*** Redacted] (such as [*** Redacted],
[*** Redacted], [*** Redacted], and [*** Redacted] etc.), having at least
[*** Redacted] that are subsequently [*** Redacted] as such nanomaterials
[*** Redacted]; (ii) any [*** Redacted], [*** Redacted], or [*** Redacted]
incorporating such [*** Redacted]; and (iii) all applications and products
incorporating [*** Redacted] that rely on such materials.

         1.10 "DuPont [*** Redacted] Technology" means (i) any method for
fabricating [*** Redacted], where such [*** Redacted] is enabled by
[*** Redacted]; (ii) any [*** Redacted] used in such methods; and (iii) all
applications and products incorporating [*** Redacted] that rely on such
methods.

         1.11 "Conventional Materials" means traditional semiconducting polymers
and semiconducting organic materials such as pentacene; carbon nanotubes; and
traditional, continuous inorganic semiconductor [*** Redacted] such as [***
Redacted] and [*** Redacted], including those having at least one cross
sectional dimension of [*** Redacted].

         1.12 "Nanosys' Exclusive Field" means compositions, devices, articles,
and methods involving or involved in Nanosys [*** Redacted] Nanomaterials
Technology, but excluding Conventional Materials, except including
[*** Redacted] when used in an architecture such that [*** Redacted] (e.g.
substantially similar to replacing the nanowives in the applications described
in Nanosys' Nature Paper (Duan et al, Nature, 425, p 274, 2003) with
[*** Redacted]).

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -2-
<PAGE>
          1.13 "DuPont's Exclusive Field" means compositions (including without
limitation Conventional Materials), devices, articles, and methods involving or
involved in Dupont [*** Redacted] Technology, but excluding Conventional
Materials used in conjunction with Nanosys [*** Redacted] Nanomaterials
Technology, and excluding [*** Redacted] when used in an architecture such that
[*** Redacted] (e.g. substantially similar to replacing the nanowives in the
applications described in Nanosys' Nature Paper (Duan et al, Nature, 425, p 274,
2003) with [*** Redacted]). For the avoidance of doubt, Conventional Processes
used in conjunction with Nanosys [*** Redacted] Nanomaterials Technology are not
in DuPont's Exclusive Field nor in Nanosys' Exclusive Field.

          1.14 "Overlap Field" means the fields which fall within both Nanosys'
Exclusive Field and DuPont's Exclusive Field.

          1.15 "Confidential Information" is defined in Section 6 below.

          1.16 "Joint Developments" is defined in Section 4.4 below.

          1.17 "Filing" means any application for or registration of a patent,
patent right (or similar right under foreign law), utility model, copyright or
mask work right with respect to Collaboration Technology.

          1.18 "Collaboration Right" means any patent, patent right (or similar
right under foreign law), utility model, copyright or mask work right issued or
registered as a result of a Filing.

     2. COLLABORATION WORK.

          2.1 Each party shall use its commercially reasonable efforts to
perform its Collaboration obligations as set forth in Exhibit A. It is
understood and agreed that the Collaboration is in the nature of research, that
successful completion of the research is not assured, and that, so long as a
party uses its commercially reasonable efforts as set forth in the preceding
sentence, that party will not be in default for any failure to achieve any
particular result or to complete any particular deliverable. The parties shall
commence the Collaboration January 22, 2004.

          2.2 Nanosys agrees to allocate to the Collaboration the number of
full-time equivalent individuals (FTEs) specified in the SOW.

          2.3 Where appropriate and agreed in each case, and in accordance with
the SOW, either party's employees may work with the other party at the other
party's facility. All employees of one party visiting the other party's facility
shall comply with the rules and regulations applicable at that facility, as
communicated to such employees.

          2.4 Any and all materials supplied by one party to the other party
shall be used by the recipient only to perform its Collaboration obligations.

***  Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -3-
<PAGE>

          2.5 Except as set forth in Section 3 below, each party shall bear its
own costs and expenses in carrying out the Collaboration.

          2.6 The following persons ("Collaboration Managers") shall be
appointed to direct the conduct of the parties with respect to the
Collaboration:

                                (a) For DuPont:

                                    Dr. Kurt L. Adams
                                    Research Manager, DuPont CR&D
                                    Experimental Station, E328/225
                                    Rt. 41 Between Rt. 202 & 52
                                    Wilmington, DE 19880-0356
                                    Phone: 302-695-7878
                                    fax: 302-695-7742
                                    E-mail: Kurt.L.Adams@usa.dupont.com

                                (b) For Nanosys:

                                    Stephen Empedocles
                                    Director, Business Development
                                    Nanosys Inc.
                                    2625 Hanover Street
                                    Palo Alto, CA 94304
                                    Phone: (650) 331-2103
                                    fax: (650) 331-2101
                                    E-mail: sempedocles@nanosysinc.com

The Collaboration Managers shall have the authority to approve in writing
changes to Exhibit A, including, as applicable, specifications, scope of work,
and milestones. The Collaboration Managers shall have no other authority to
amend this Agreement. Each party may change its Collaboration Manager on written
notice to the other party, provided that the replacement Collaboration Manager
is at a similar level of authority at the party making the replacement, or as
otherwise agreed to by the parties.

          2.7 If either party desires to propose changes to the Collaboration,
it shall notify the other party in writing of such proposal and the reasons for
such proposal. The other party will give each such proposal its prompt
attention. If DuPont and Nanosys agree to any such change, the change shall be
evidenced by a written confirmation signed by the Collaboration Managers of both
parties. Such a written confirmation shall amend Exhibit A.

                                                                             -4-
<PAGE>

     3. PAYMENTS TO NANOSYS.

          3.1 DuPont shall pay to Nanosys the following payments at the
following times:

<TABLE>
<CAPTION>
                      Time of Payment                                                        Amount of Payment
                      ---------------                                                        -----------------
<S>                                                                                          <C>
Collaboration Commencement Date

Three (3) months after the Collaboration Commencement Date                                   $ [*** Redacted]

Six (6) months after the Collaboration Commencement Date                                     $ [*** Redacted]

Nine (9) months after the Collaboration Commencement Date                                    $ [*** Redacted]
</TABLE>

* These amounts (for the latter three (3) quarters) are nonbinding estimates of
the effort that may be required from Nanosys in these quarters, based on
experience in similar investigations. These estimates may be revised on a
quarterly basis based on the learnings from the previous quarter. All amounts
are and will be based on a rate of [*** Redacted] per FTE-quarter.

For the avoidance of doubt, the latter [***  Redacted] payments will not be due
if this Agreement terminates under Section 10.2 below.

     4. OWNERSHIP.

          4.1 Each party shall retain its ownership of its Background IP. No
rights are granted pursuant to this Agreement with respect to any Background IP.

          4.2 Whether Collaboration Technology is jointly or solely made shall
be determined according to United States patent law or, as to original works of
authorship, according to United States copyright law. Except as to patent
ownership, all other questions concerning the construction or effect of patent
applications and patents shall be decided in accordance with the laws of the
country in which the particular patent application concerned has been filed or
granted.

          4.3 Each of Nanosys and DuPont shall own the Collaboration Technology
solely made by its respective employees, agents, and contractors. Subject to
Sections 4.5, 5, 6, and 7 below, sole ownership of Collaboration Technology
shall vest in the owning party the exclusive right to determine whether and how
the Collaboration Technology and the associated intellectual property rights are
to be protected and exercised throughout the world.

          4.4 Nanosys and DuPont shall jointly own jointly made Collaboration
Technology ("Joint Developments"), with no duty to account, and, subject to
Sections 4.5, 5, 5, 6, and 7 below, each party shall have the right to use and
exploit such Joint Developments without consent of the

***  Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portion
have been filed separately with the Commission.

                                                                             -5-
<PAGE>

other party. Each party waives any rights under applicable law that it may have
to require consent or an accounting. Subject to Sections 4.5, 5, 6, and 7 below,
joint ownership of Collaboration Technology and the associated intellectual
property rights shall vest in the parties the joint right to determine whether
and how the Collaboration Technology and the associated intellectual property
rights are to be protected and exercised throughout the world.

          4.5 Each party agrees that it will not use any of its solely owned or
jointly owned Collaboration Technology (or any associated solely owned or
jointly owned Collaboration IP) in the Overlap Field, except as may be agreed by
the parties in writing. If either party desires to use any such Collaboration
Technology and/or Collaboration IP in the Overlap Field, it may provide written
notice to the other party, in appropriate detail, of the proposed scope of such
use. Within ninety (90) days after such notice, the other party shall, by
written notice to the original notifying party, respond either (i) granting
permission for such use, or (ii) offering to negotiate the terms and conditions
of such use, it being understood that neither party shall be obligated to enter
into any particular agreement or arrangement, nor shall either party be
obligated to enter into any agreement or arrangement that is inconsistent with
its then current obligations to third parties. Any failure to so respond within
this ninety (90) day period shall be irrevocably deemed permission for the
originally notifying party to use such Collaboration Technology and/or
Collaboration IP as proposed in the original party's notice. With respect to
Collaboration IP for which permission is so granted, to the extent such
Collaboration IP is solely owned by the party granting such permission, such
party shall be deemed to have granted to the other party a worldwide,
nontransferable (except as set forth in Section 11.7 below), royalty free
license, only under such Collaboration IP, to design, develop, make, have made,
use, import, offer to sell, and sell or distribute any product or item and to
practice any method or process, in each case limited to the scope of use
specified in the licensee's notice provided as set forth hereinabove.

     5. LICENSES.

          5.1 Subject to the terms and conditions of this Agreement, Nanosys
agrees to grant, and hereby grants, to DuPont a worldwide, nonexclusive (except
as set forth in Section 5.1(i) hereinbelow), nontransferable (except as set
forth in Section 11.7 below), royalty free license, only under the Nanosys
Collaboration IP, to design, develop, make, have made, use, import, offer to
sell, and sell or distribute any product or item and to practice any method or
process, provided that:

                    (i) this license shall be exclusive (including as to
Nanosys) for use of the Nanosys Collaboration IP in DuPont's Exclusive Field,
subject to Section 5.1(ii) below, and

                    (ii) no license is granted by Nanosys for use of any Nanosys
Collaboration IP in Nanosys' Exclusive Field (it being understood that Nanosys'
Exclusive Field includes, without limitation, the Overlap Field).

          5.2 Subject to the terms and conditions of this Agreement, DuPont
agrees to grant, and hereby grants, to Nanosys a worldwide, nonexclusive (except
as set forth in Section 5.2(i) hereinbelow), nontransferable (except as set
forth in Section 11.7 below), royalty free license, only under the DuPont
Collaboration IP, to design, develop, make, have made, use, import, offer to
sell, and sell or distribute any product or item and to practice any method or
process, provided that:

                                                                             -6-
<PAGE>

                    (i) this license shall be exclusive (including as to DuPont)
for use of the DuPont Collaboration IP in Nanosys' Exclusive Field, subject to
Section 5.2(ii) below, and

                    (ii) no license is granted by DuPont for use of any DuPont
Collaboration IP in DuPont's Exclusive Field (it being understood that DuPont's
Exclusive Field includes, without limitation, the Overlap Field).

          5.3 Each party shall have the right to grant sublicenses (and
authorize the granting of further sublicenses) under the license granted to it
in Section 5.1 or 5.2 above, as applicable.

          5.4 No party shall be obligated to provide any Technology or
deliverable in connection with the licenses granted in this Section 5; all
deliverables under this Agreement are specified exclusively in Exhibit A.

     6. CONFIDENTIAL INFORMATION.

          6.1 The term "Confidential Information" shall mean any information or
materials disclosed by one party to the other, pursuant to this Agreement, which
is in written, graphic, machine readable or other tangible form and is marked
"Confidential", "Proprietary" or in some other manner to indicate its
confidential nature. Confidential Information may also include oral information
disclosed by one party to the other, provided that such information is
designated as confidential at the time of disclosure and reduced to a written
summary by the disclosing party, within thirty (30) days after its oral
disclosure or disclosure resulting from such access, which written summary is
marked in a manner to indicate its confidential nature and delivered to the
receiving party. Confidential Information shall also include any information
disclosed as a result of access to the other party's premises or property.

          6.2 Each party shall treat as confidential all Confidential
Information of the other party, shall not use such Confidential Information
except for the Collaboration, shall implement reasonable procedures to prohibit
the disclosure, unauthorized duplication, misuse or removal of the other party's
Confidential Information, and shall not disclose such Confidential Information
to any third party except as reasonable and necessary to exercise its rights and
perform its obligations pursuant to this Agreement, and under substantially
similar restrictions as those set forth in this section. Without limiting the
foregoing, each party shall use at least the same procedures and degree of care
which it uses to prevent the disclosure or misuse of its own confidential
information of like importance to prevent the disclosure or misuse of
Confidential Information disclosed to it by the other party under this
Agreement, but in no event less than reasonable care.

          6.3 Notwithstanding the above, neither party shall have liability to
the other with regard to any Confidential Information of the other which:

                    (i) was generally known and available at the time it was
disclosed or becomes generally known and available through no fault of the
receiving party;

                    (ii) was known to the receiving party, without restriction,
at the time of disclosure as shown by the files of the receiving party in
existence at the time of disclosure;

                                                                             -7-
<PAGE>

                    (iii) is disclosed with the prior written approval of the
disclosing party;

                    (iv) was independently developed by the receiving party
without any use of the Confidential Information and by employees or other agents
of the receiving party who have not been exposed to the Confidential
Information, provided that the receiving party can demonstrate such independent
development by documented evidence prepared contemporaneously with such
independent development; or

                    (v) becomes known to the receiving party, without
restriction, from a source other than the disclosing party without breach of
this Agreement by the receiving party and otherwise not in violation of the
disclosing party's rights.

In addition, each party shall be entitled to disclose the other party's
Confidential Information to the extent such disclosure is required by the order
or requirement of a court, administrative agency, or other governmental body;
provided, that the party required to make the disclosure shall provide prompt,
advance notice thereof to enable the other party to seek a protective order or
otherwise prevent such disclosure.

     7. INTELLECTUAL PROPERTY PROTECTION.

          7.1 Nanosys and DuPont Collaboration Technology. Nanosys shall have
the sole right at its expense to prepare, file and prosecute Filings related to
any Collaboration Technology solely owned by Nanosys and to maintain
Collaboration Rights issued thereon. DuPont shall have the sole right at its
expense to prepare, file and prosecute Filings related to any Collaboration
Technology solely owned by DuPont and to maintain Collaboration Rights issued
thereon.

          7.2 Joint Developments. The parties shall confer on (i) protection of
Joint Developments through Filings on the Joint Development and/or through
maintenance of the Joint Development as a trade secret, and (ii) preparation,
filing, prosecution and maintenance of Filings and Collaboration Rights related
to Joint Developments. The parties shall agree by whom Filings will be done in a
country for a particular Joint Development. If only one party wants to protect a
Joint Development through a Filing on that Joint Development, then that party
shall be entitled to do so, at its sole expense and in its own name. If both
parties share the expense of such Filing, then the Filing shall be made on
behalf of both parties and shall name each party as joint and equal owner in
such country of the Joint Development and of the resulting Collaboration Right.
If one party does not share the expense of such Filing, then the Filing shall be
made on behalf of the party which makes the Filing and shall name such party as
the sole owner in such country of the Collaboration Right pertaining to such
Joint Development, and the party which makes the Filing shall be deemed to have
granted the other party a nonexclusive (except as set forth hereinbelow),
irrevocable, perpetual, fully paid, royalty free license, with right to
sublicense (and authorize the granting of further sublicenses), only under such
Collaboration Right, without restriction, including to practice any process or
method, and to design, develop, make, use, have made, offer to sell, and sell or
distribute any product or item, provided that (A) in the case of such license
from Nanosys to DuPont (I) this license shall be exclusive (including as to
Nanosys) for use of the Collaboration Right in DuPont's Exclusive Field, subject
to clause (A)(II) hereinbelow, and (II) no license is granted by

                                                                             -8-
<PAGE>

Nanosys for use of the Collaboration Right in Nanosys' Exclusive Field (it being
understood that Nanosys' Exclusive Field includes, without limitation, the
Overlap Field); and (B) in the case of such a license from DuPont to Nanosys (I)
this license shall be exclusive (including as to DuPont) for use of the
Collaboration Right in Nanosys' Exclusive Field, subject to clause (B)(II)
hereinbelow, and (II) no license is granted by DuPont for use of the
Collaboration Right in DuPont's Exclusive Field (it being understood that
DuPont's Exclusive Field includes, without limitation, the Overlap Field). If
either party does not pay its one-half share of maintenance expenses with
respect to a Collaboration Right, then sole ownership of that Collaboration
Right shall be transferred and assigned to the other party, subject to a license
to the non-owning party as set forth hereinabove.

          7.3 Infringement Prosecution.

               (a) (i) Nanosys shall have the sole right to prosecute claims of
infringement or misappropriation of Collaboration Rights (whether owned by
Nanosys, owned by DuPont, or jointly owned by Nanosys and DuPont) or
misappropriation of any trade secret with respect to Collaboration Technology
(whether of Nanosys, of DuPont, or jointly of Nanosys and DuPont), where such
infringement or misappropriation is primarily in Nanosys' Exclusive Field. In
each such case, DuPont shall, at Nanosys' expense, take all actions reasonably
requested by Nanosys in such prosecution (which may include participation as a
named plaintiff, subject to indemnification by Nanosys of DuPont for any
liability to third parties resulting from such participation as a plaintiff).

                    (ii) DuPont shall have the sole right to prosecute claims of
infringement or misappropriation of Collaboration Rights (whether owned by
Nanosys, owned by DuPont, or jointly owned by Nanosys and DuPont) or
misappropriation of any trade secret with respect to Collaboration Technology
(whether of Nanosys, of DuPont, or jointly of Nanosys and DuPont), where such
infringement or misappropriation is primarily in DuPont's Exclusive Field. In
each such case, Nanosys shall, at DuPont's expense, take all actions reasonably
requested by DuPont in such prosecution (which may include participation as a
named plaintiff, subject to indemnification by DuPont of Nanosys for any
liability to third parties resulting from such participation as a plaintiff).

                    (iii) For the avoidance of doubt, the determination of
whether any infringement or misappropriation is primarily in Nanosys Exclusive
Field or Dupont's Exclusive field shall be determined by good-faith discussions
between the parties, when such infringement or misappropriation occurs in the
Overlap Field. Regardless of this determination, either party shall have the
right to prosecute claims of infringement or misappropriation of Collaboration
Rights (whether owned by Nanosys, owned by DuPont, or jointly owned by Nanosys
and DuPont) or misappropriation of any trade secret with respect to
Collaboration Technology (whether of Nanosys, of DuPont, or jointly of Nanosys
and DuPont), where such infringement or misappropriation is in the Overlap
Field, if the other party chooses not to pursue such prosecution. In each such
case, the obligations of Nanosys and DuPont to support a prosecution initiated
by the other party shall be as set forth in paragraphs (i) and (ii) of this
Section 7.3(a).

               (b) Except as set forth in Section 7.3(a) above, each party shall
have the sole right to prosecute claims of infringement of any Collaboration
Right owned solely by such party

                                                                             -9-
<PAGE>

or infringement or misappropriation of any trade secret with respect to
Collaboration Technology owned solely by such party.

               (c) Except as set forth in Section 7.3(a) above, if either party
(the "Notifying Party") wishes to commence an action against a third party for
actual or potential infringement or misappropriation ("Infringement") of any
jointly owned Joint Development or related jointly owned Collaboration Right,
then such party shall promptly so notify the other party (the "Other Party") in
writing of such Infringement (the "Infringement Notice"), and the following
shall apply:

                    (i) The Notifying Party shall have the sole right to
prosecute such Infringement for a period of ninety (90) days after the date
of the Infringement Notice, provided that the Other Party may, by written notice
within thirty (30) days after the Infringement Notice, elect to participate
in the Infringement action and agree to pay one-half of the costs of such
prosecution. In such event, the parties shall jointly control and cooperate in
prosecution of such Infringement action and shall share equally in any monetary
award resulting from such prosecution.

                    (ii) If the Other Party elects to participate and share
costs as set forth in Section 73(c)(i), but the Notifying Party does not take
reasonable actions to prosecute the Infringement action before the end of such
ninety (90) day period, or notifies the Other Party that it does not intend
to prosecute such Infringement, then (A) the Other Party shall have the sole
right for sixty (60) days at its expense to prosecute such Infringement and
retain any monetary award resulting therefrom, and (B) the Notifying Party
shall, at the Other Party's expense, take all actions reasonably requested by
the Other Party in such prosecution (which may include participation as a named
plaintiff, subject to indemnification by the Other Party of the Notifying Party
for any liability to third parties resulting from such participation as a
plaintiff). If the Other Party does not take reasonable actions to prosecute
such Infringement action before the end of such sixty (60) day period, or
notifies the Notifying Party that it does not intend to prosecute such
Infringement, then Section 7.3(c) shall become applicable again.

                    (iii) If the Other Party does not elect to participate and
share expenses as set forth in Section 7.3(c)(i):

                         (A) If the Notifying Party takes reasonable actions to
prosecute the Infringement action during the ninety (90) days after the date of
the Infringement Notice, then (I) the Notifying Party shall have the sole right
to prosecute such Infringement and retain any monetary award resulting
therefrom, and (II) the Other Party shall, at the Notifying Party's expense,
take all actions reasonably requested by the Notifying Party in such prosecution
(which may include participation as a named plaintiff, subject to
indemnification by the Notifying Party of the Other Party for any liability to
third parties resulting from such participation as a plaintiff).

                         (B) If the Notifying Party does not take reasonable

actions to prosecute the Infringement action before the end of such
ninety (90) day period, or notifies the Other Party that it does not intend
to prosecute such Infringement, then Section 7.3(c) shall become applicable
again.

                                                                            -10-
<PAGE>

                    (iv) If a party prosecutes an Infringement and the other
party does not bear one-half the costs of such prosecution as set forth above,
then the prosecuting party shall retain the entire amount of any monetary award
resulting from such prosecution.

               (d) If a party prosecuting an Infringement action with respect to
any jointly owned Joint Development or jointly owned Collaboration Right on its
own abandons the Infringement action, then Section 7.3(c) above shall again
apply with respect to that Infringement.

          7.4 Further Assurances. At any time or from time to time on and after
the date of this Agreement, each party shall at the request of the other party
(i) execute, and deliver or cause to be delivered, all such consents, documents
or further instruments of license, and (ii) take or cause to be taken all such
other actions, in each case as the other party may reasonably deem necessary or
desirable in order for the other party to obtain the full benefits of this
Section 7 and the activities contemplated hereby.

     8. WARRANTY DISCLAIMER.

     NEITHER NANOSYS NOR DUPONT MAKES ANY WARRANTY OF ANY KIND, WHETHER EXPRESS,
IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING THE
FOREGOING, ALL DELIVERABLES AND OTHER ITEMS ARE PROVIDED BY EACH PARTY "AS IS,"
AND ALL LICENSES GRANTED BY EACH PARTY ARE GRANTED "AS IS."

     9. LIMITATION OF LIABILITY.

     NEITHER PARTY SHALL HAVE ANY LIABILITY FOR COSTS OF SUBSTITUTE PRODUCTS OR
SERVICES, OR FOR ANY INCIDENTAL, CONSEQUENTIAL, INDIRECT, SPECIAL OR INDIRECT
DAMAGES OR LIABILITIES, INCLUDING WITHOUT LIMITATION SUCH DAMAGES OR LIABILITIES
FOR LOSS OF REVENUE, LOSS OF BUSINESS, FRUSTRATION OF ECONOMIC OR BUSINESS
EXPECTATIONS, LOSS OF PROFITS, OR COST OF CAPITAL, REGARDLESS OF THE FORM OF THE
ACTION, WHETHER IN CONTRACT OR OTHERWISE, EVEN IF ANY REPRESENTATIVE OF A PARTY
HERETO HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL
EITHER PARTY'S LIABILITY UNDER THIS AGREEMENT EXCEED THE AMOUNTS PAID OR PAYABLE
BY DUPONT TO NANOSYS UNDER THIS AGREEMENT, provided that, as to DuPont, this
shall be in addition to DuPont's obligation to pay such amounts. These
limitations, however, shall not apply to either party's liability, if any, (i)
for contribution or indemnity with respect to liability to third parties for
personal injury, death, or damage to tangible property, (ii) exceeding the scope
of the licenses in Section 5 (Licenses), (iii) breach of Section 6 (Confidential
Information), or (iv) infringement of the other party's intellectual property
rights.

                                                                            -11-

<PAGE>

     10. TERM AND TERMINATION.

          10.1 Term. This Agreement shall commence as of the Effective Date and,
subject to Section 10.2 below, shall continue until January 22, 2005 unless
earlier terminated as set forth herein.

          10.2 Q1 Checkpoint. This Agreement shall terminate three (3) months
after the Collaboration Commencement Date, unless the parties have agreed, in a
writing referencing this Section 10.2, to continue the Collaboration under this
Agreement.

          10.3 Termination Due to Bankruptcy, etc. In the event a party: (i)
becomes insolvent; (ii) voluntarily files or has filed against it a petition
under applicable bankruptcy or insolvency laws which such party fails to have
released within thirty (30) days after filing; (iii) proposes any dissolution,
composition or financial reorganization with creditors or if a receiver,
trustee, custodian or similar agent is appointed or takes possession with
respect to all or substantially all property or business of such party; or (iv)
such party makes a general assignment for the benefit of creditors; then the
other party may terminate this Agreement by notice to the non-terminating party.

          10.4 Termination Due to Breach. Either party shall have the right to
terminate this Agreement if the other party is in material breach of any
material term or condition of this Agreement and fails to remedy such breach
within thirty (30) days after receipt of written notice of such breach given by
the non-breaching party. To terminate this Agreement, the nonbreaching party
must provide further written notice of such termination to the breaching party
prior to a cure of the breach.

          10.5 Survival. Neither the termination nor expiration of this
Agreement shall relieve either party from its obligations to pay the other any
sums accrued hereunder. Upon the termination or expiration of this Agreement,
(i) DuPont shall promptly return, or certify the destruction of, to Nanosys all
Nanosys Confidential Information, except for such Nanosys Confidential
Information as may be reasonable and necessary for DuPont to exercise its
surviving rights and licenses under this Agreement, and (ii) Nanosys shall
promptly return, or certify the destruction of, to DuPont all DuPont
Confidential Information, except for such DuPont Confidential Information as may
be reasonable and necessary for Nanosys to exercise its surviving rights and
licenses under this Agreement. The parties agree that their respective rights,
obligations and duties under Sections 4 (Ownership), 5 (Licenses), 6
(Confidential Information), 7 (Intellectual Property Protection), 8 (Warranty
Disclaimer), 9 (Limitation of Liability), 10.5 (Survival), and 11
(Miscellaneous) shall survive any termination or expiration of this Agreement.

     11. MISCELLANEOUS.

          11.1 Publicity. Any press release or other public announcement with
respect to this Agreement shall be subject to the mutual agreement of the
parties, which agreement shall not be unreasonably withheld.

                                                                            -12-
<PAGE>

          11.2 Notices. All notices, requests, demands and other communications
given or made in accordance with the provisions of this Agreement shall be in
writing and shall be deemed to have been given (i) three days after mailing when
mailed (by registered or certified mail, postage paid, only), (ii) on the date
sent when made by facsimile transmission with confirmation of receipt (with hard
copy to follow by registered or certified mail, postage paid, only), and (iii)
on the date received when delivered in person or by courier, provided that
notices and communications with respect to administrative and project matters
(e.g., changes in meeting times and dates, program specifications, and specific
program development activities) (but not legal matters or matters pertaining to
or establishing rights under this Agreement), may be provided by e-mail and will
be deemed given when sent. All notices shall be provided to the address set
forth below or such other place as such party may from time to time designate in
writing. Each party may alter its address set forth below by notice in writing
to the other party, and such notice shall be considered to have been given three
(3) days after the sending thereof

                      If to Nanosys: Nanosys Inc.
                                     2625 Hanover Street
                                     Palo Alto, California 94304
                                     Fax: (650) 331-2101
                                     Attn: Calvin Y.H. Chow
                                     E-mail: cchow@nanosysinc.com

     with a copy, for matters pertaining to intellectual property, to:

                                     Nanosys Inc.
                                     2625 Hanover Street
                                     Palo Alto, California 94304
                                     Fax: (650) 331-2101
                                     Attn: Matt Murphy
                                     E-mail: mmurphy@nanosysinc.com

                       If to DuPont: Planning Manager, DuPont CR&D
                                     Experimental Station, E328/409
                                     Rt. 41 Between Rt. 202 & 52
                                     Wilmington, DE 19880-0356
                                     Phone: 302 695-4571
                                     Fax: 302-695-4571
                                     E-mail:
                                     Krishna.C.Doraiswamy@usa.dupont.com

                                                                            -13-
<PAGE>

     with a copy, for matters pertaining to intellectual property, to:

                                   Barbara C. Sugell, Esg.
                                   DuPont Legal
                                   Barley Mill Plaza 25-1218
                                   Wilmington, DE 19880-0025
                                   Fax: 302-992-5374
                                   E-mail: Krishna.C.Doraiswamy@usa.dupont.com

          11.3 Amendment; Waiver. This Agreement may be amended, modified or
supplemented only by a writing that is signed by duly authorized representatives
of both parties and that specifically identifies the provision or provisions of
this Agreement being amended, modified or supplemented. No term or provision
hereof will be considered waived by either party, and no breach excused by
either party, unless such waiver or consent is in writing signed on behalf of
the party against whom the waiver is asserted. Without limiting the foregoing,
no consent by either party to, or waiver of, a breach by either party, whether
express or implied, will constitute a consent to, waiver of, or excuse of any
other, different, or subsequent breach by either party.

          11.4 Severability. If any provision hereof should be held invalid,
illegal or unenforceable in any jurisdiction, the parties shall negotiate in
good faith a valid, legal and enforceable substitute provision that most nearly
reflects the original intent of the parties and all other provisions hereof
shall remain in full force and effect in such jurisdiction and shall be
liberally construed in order to carry out the intentions of the parties hereto
as nearly as may be possible. Such invalidity, illegality or unenforceability
shall not affect the validity, legality or enforceability of such provision in
any other jurisdiction.

          11.5 Governing Law. This Agreement shall be governed by and construed
under the laws of the United States and the State of California, not including
its conflict of law provisions.

          11.6 Force Majeure. Except for the payment of money, neither party
will be liable for any failure or delay in performance under this Agreement due
to fire, explosion, earthquake, storm, flood or other weather, unavailability of
necessary utilities or raw materials, war, insurrection, riot, act of God or the
public enemy, law, act, order, proclamation, decree, regulation, ordinance, or
instructions of government or other public authorities, or any other event
beyond the reasonable control of the party whose performance is to be excused.
If, however, a party's performance is prevented for sixty (60) days, then
the other party shall be entitled to terminate this Agreement on written notice
to the party suffering the force majeure at any time prior to resumption of
performance by the party suffering the force majeure.

          11.7 Assignment. Neither party may transfer or assign this Agreement,
whether by operation of law or otherwise, without the prior written consent of
the other party and any attempt to do so without such consent will be void. This
Agreement will bind and inure to the benefit of the parties and their respective
permitted successors and permitted assigns. Notwithstanding anything in this
Agreement, however, either party may assign this Agreement without the other
party's prior written consent to a successor to all or substantially all of its
assets pertaining to the Collaboration

                                                                            -14-
<PAGE>

(e.g., the surviving entity in a merger or consolidation in which it
participates or to a purchaser of all or substantially all of its assets
pertaining to the Collaboration), so long as such surviving entity or purchaser
shall assume (expressly in writing or by operation of law) the performance of
all of the terms of this Agreement.

          11.8 No Third Party Beneficiaries. No person or entity other than
DuPont and Nanosys will have any rights or obligations pursuant to this
Agreement.

          11.9 Relationship of the Parties. The parties to this Agreement are
independent contractors. There is no relationship of agency, partnership, joint
venture, employment, or franchise between the parties and this Agreement is
negotiated at arm's length with both sides represented by counsel of their
choice. Neither party has the authority to bind the other or to incur any
obligation on its behalf. Any such act will create a separate liability in the
party so acting to any and all third parties affected thereby.

          11.10 Counterparts. This Agreement maybe executed in two counterparts,
each of which shall be deemed an original, but both of which together shall
constitute one and the same instrument. If this Agreement is executed in
counterparts, no signatory hereto shall be bound until both the parties named
below have duly executed or caused to be duly executed a counterpart of this
Agreement.

          11.11 Confidentiality of Agreement: Each party agrees that the terms
and conditions, but not the existence or general nature, of this Agreement shall
be treated as confidential, provided, however, that each party may disclose the
terms and conditions of this Agreement: (i) as required by any court or other
governmental body; (ii) as otherwise required by law; (iii) to legal counsel of
the parties; (iv) in connection with the requirements of a public offering or
securities filing; (v) in confidence, to accountants, banks, and financing
sources and their advisors; (vi) in confidence, in connection with the
enforcement of this Agreement or rights under this Agreement; or (vii) in
confidence, in connection with a merger or acquisition or proposed merger or
acquisition, or the like.

          11.12 Authority. Each party represents and warrants to the other party
at the Effective Date (i) that it has the legal right, power, and authority to
enter into this Agreement and to fully perform its obligations under this
Agreement, and (ii) that the performance of such obligations will not conflict
with any agreements, contracts or other arrangements to which it is a party or
by which it is bound.

          11.13 Entire Agreement. This Agreement, including all Exhibits to this
Agreement, constitutes the entire agreement between the parties relating to this
subject matter and supersedes all prior or simultaneous representations,
discussions, negotiations, letters of intent, term sheets, and agreements,
whether written or oral, with respect to the subject matter hereof (including,
without limitation, any prior non-disclosure agreement entered into by Nanosys
and DuPont).

                                                                            -15-
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the
dates set forth below effective as of the Effective Date.

NANOSYS INC.                             E.I. DU PONT DE NEMOURS AND COMPANY

By: /s/ Calvin Chow                      By: James C. Romine

Print Name: Calvin Chow                  Print Name: James C. Romine

Title:  Chief Executive Officer          Title: Science Director

Date: 1-20-04                            Date: Jan. 20, 2004

                                                                            -16-
<PAGE>

                                    EXHIBIT A

                      Collaboration Statement of Work (SOW)

FIRST QUARTER ACTIVITIES:

TASK O: PRELIMINARY WORK

Milestone:  Set-up for Tasks 1 and 2.

<TABLE>
<CAPTION>
        SUBTASK                                   DESCRIPTION                                     DELIVERABLES
        -------                                   -----------                                     ------------
<S>                                   <C>                                                       <C>

Order [*** Redacted] etc [Nanosys]    -     Order [*** Redacted]                                Materials required for task 2

                                      -     Order required [*** Redacted]
                                            tools to [*** Redacted] in
                                            the [*** Redacted] of [*** Redacted].

[*** Redacted] [Nanosys]              Fabricate [*** Redacted] to                               Capability of [*** Redacted]
                                      [*** Redacted] from                                       samples. [*** Redacted]
                                      [*** Redacted] to [*** Redacted].

Examine [*** Redacted]  [DuPont]      -     Measure [*** Redacted] of [*** Redacted]            [*** Redacted]
                                            conductors.

                                      -     Establish [*** Redacted] for [*** Redacted] of
                                            the [*** Redacted]

Prepare [*** Redacted]  [DuPont]       Prepare [*** Redacted] and [*** Redacted] Nanosys         [*** Redacted] on [*** Redacted] of
                                                                                                 [*** Redacted]
</TABLE>

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.
<PAGE>

TASK 1: TRANSISTOR PERFORMANCE TARGETS

Milestone: Specify near-term and long-term performance targets for
[*** Redacted].

<TABLE>
<CAPTION>
            SUBTASK                              DESCRIPTION                                             DELIVERABLES
            -------                              -----------                                             ------------
<S>                                 <C>                                                    <C>
Define [*** Redacted] performance   Near-term and long-term specifications,                DuPont provides written requirements for
targets [DuPont]                    including:                                             near-term ([*** Redacted]) and long-term
                                                                                           ([*** Redacted]) performance
                                    -    [*** Redacted]

                                    -    [*** Redacted]

                                    -    [*** Redacted]

                                    -    [*** Redacted]

                                    -    [*** Redacted]

                                    -    [*** Redacted]
</TABLE>

TASK 2: ASSESS [*** Redacted] for [*** Redacted] for [*** Redacted] to the
[*** Redacted]

Milestone: Determine appropriate [*** Redacted] for [*** Redacted] to the
[*** Redacted], or determine that [*** Redacted] is not a suitable for use with
[*** Redacted].

<TABLE>
<CAPTION>
         SUBTASK                                              DESCRIPTION                                  DELIVERABLES
         -------                                              -----------                                  ------------
<S>                                 <C>                                                                    <C>
Prepare [*** Redacted]              -     Use [*** Redacted]                                                   None
[Nanosys]
                                    -     Use [*** Redacted] to [*** Redacted] in
                                          the [*** Redacted] of [*** Redacted]
</TABLE>

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                      -2-
<PAGE>
<TABLE>
<CAPTION>
           SUBTASK                              DESCRIPTION                           DELIVERABLES
           -------                              -----------                           ------------
<S>                                 <C>                                   <C>
Determine [*** Redacted]            -    Allow for [*** Redacted]         Evaluation of [*** Redacted]
[Nanosys]                                on the [*** Redacted]            and [*** Redacted]
                                                                          and [*** Redacted].

                                    -    [*** Redacted]

                                    -    Measure [*** Redacted]
                                         the [*** Redacted]

                                    -    [*** Redacted] in [*** Redacted]
</TABLE>

TASK 3: [*** Redacted] SYNTHESIS, [*** Redacted] AND SUPPLY

Milestone: Supply [*** Redacted] for [*** Redacted] testing in Task 4, and
electrical testing in Tasks 5 and 6.

<TABLE>
<CAPTION>
           SUBTASK                              DESCRIPTION                             DELIVERABLES
           -------                              -----------                             ------------
<S>                                 <C>                                   <C>
Fabricate [*** Redacted] for        -    Standard [*** Redacted]          [*** Redacted] for use in Task 4
[*** Redacted] testing (no                                                Task 4
[*** Redacted] specification)
[Nanosys]
                                    -   [*** Redacted] and [*** Redacted]
                                        [*** Redacted] evaluated to
                                        [*** Redacted] onto [*** Redacted]

Fabricate [*** Redacted] with       -  [*** Redacted]                     -    [*** Redacted] for Task 5
[*** Redacted] selected based on
results of Task 2 [Nanosys]         -    [*** Redacted] selected based    -    [*** Redacted] for Task 6
                                         on Task 2

                                    -    [*** Redacted] optimization
                                         based on results of Task 5
</TABLE>

                                                                             -3-

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

<PAGE>

TASK 4: DETERMINE WHETHER [*** Redacted] and [*** Redacted] are compatible

Milestone: Determine whether [*** Redacted] can be [*** Redacted] by one or more
     [*** Redacted] methods.

Remarks: We have identified [*** Redacted] potential routes for incorporating
     the [*** Redacted] into the [*** Redacted]: [*** Redacted], [*** Redacted],
     and [*** Redacted]. All [*** Redacted] routes will be explored in parallel.
     In order to expedite testing, the [*** Redacted] used in these experiments
     will be whatever is on hand in sufficient quantity, since no [*** Redacted]
     tests are envisioned.

<TABLE>
<CAPTION>
           SUBTASK                                DESCRIPTION                    DELIVERABLES
           -------                                -----------                    ------------
<S>                                 <C>                                   <C>
Prepare [*** Redacted] [DuPont]     -    [*** Redacted] will be prepared:         [*** Redacted] for [*** Redacted]
                                         [*** Redacted], [*** Redacted],
                                         and [*** Redacted].

                                    -    There will be at least [*** Redacted]
                                         [*** Redacted] of each type, and
                                         at least [*** Redacted], so the total
                                         number of [*** Redacted] will be
                                         in the [*** Redacted] range.

                                    -    The [*** Redacted] will be
                                         [*** Redacted] wide and approximately
                                         [*** Redacted].

[*** Redacted]                      -    To effectively assess                      None.
[Nanosys]                                [*** Redacted], they should have
                                         [*** Redacted] commensurate with
                                         [*** Redacted]

[*** Redacted]                      -    For the maximum of information
[*** Redacted] [Nanosys]                                with the minimum of
effort, each [*** Redacted] should have [*** Redacted].
</TABLE>

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -4-

<PAGE>

<TABLE>
<CAPTION>
           SUBTASK                                DESCRIPTION                    DELIVERABLES
           -------                                -----------                    ------------
<S>                                 <C>                                   <C>
                                    -    Selecting the [*** Redacted]
                                         will require a judgment call.
                                         It should be at least
                                         [*** Redacted], but probably not
                                         [*** Redacted]

[*** Redacted] [DuPont]             -    [*** Redacted]                      None
                                         will be [*** Redacted] to
                                         look for [*** Redacted]

                                    -    [*** Redacted]
                                         will be [*** Redacted]

                                    -    [*** Redacted]
                                         will be [*** Redacted]

Analysis of [*** Redacted]          -    A combination of [*** Redacted]     [*** Redacted] and a detailed
[DuPont]                                 and [*** Redacted] will be          report on what worked, what
                                         used to assess the results of       failed, and how it failed.
                                         these [*** Redacted].

Determine whether we have           -    Joint assessment of results.        Go/no go decision on [*** Redacted]
a viable path for [*** Redacted]
                                    -    Joint determination of
                                         possible paths forward
</TABLE>

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -5-
<PAGE>

TASK 5: BUILD [*** Redacted]

Milestone: Verify that chosen [*** Redacted] in simple test structures made
from [*** Redacted] materials.

<TABLE>
<CAPTION>
           SUBTASK                              DESCRIPTION                            DELIVERABLES
           -------                              -----------                            ------------
<S>                                 <C>                                   <C>
Build [*** Redacted] structures     Build up [*** Redacted]               [*** Redacted] test
[DuPont]                            test structures.                      structures

[*** Redacted]                      Depending on the outcome of our       [*** Redacted] test structures
test structures or [*** Redacted]   our [*** Redacted], either:           or
[Nanosys]

                                    -    [*** Redacted] will be           [*** Redacted]
                                         [*** Redacted] or:

                                    -    [*** Redacted] will be
                                         [*** Redacted] and
                                         [*** Redacted] the test structures.

Finish [*** Redacted] test          Depending on the outcome of our       [*** Redacted]
structures [DuPont]                 [*** Redacted], either:

                                    -    [*** Redacted] are
                                         [*** Redacted] test
                                         structure, or:

                                    -    [*** Redacted] and
                                         [*** Redacted] will be
                                         [*** Redacted] the test structures.

Verify [*** Redacted]               [*** Redacted]                        [*** Redacted]
[DuPont and Nanoys]
</TABLE>

TASK 6: [*** Redacted]

Milestone: Functioning [*** Redacted] that meet the [*** Redacted]
performance targets.

[*** Redacted]

At the end of this task, [*** Redacted]

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -6-

<PAGE>

TASK 7: DEVELOP A PLAN FOR ACHIEVING THE [*** Redacted] PERFORMANCE TARGETS
WITHIN THE [*** Redacted]

                             Figure 1. Gantt chart.

<TABLE>
<CAPTION>
<S>               <C>               <C>
[*** Redacted]

</TABLE>

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -7-

<PAGE>

NANOSYS PROJECT TEAM MAKEUP:

     -    [*** Redacted] Engineer (95% effort)

     -    [*** Redacted] Engineer (95% effort)

     -    [*** Redacted] Engineer (95% effort)

     -    [*** Redacted] ([*** Redacted] for 25%)
          ([*** Redacted] effort)

          Total effort during first quarter: 3.10 FTEs

*** Confidential treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission. Omitted portions
have been filed separately with the Commission.

                                                                             -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]